

## Notice of Annual General Meeting in Abera Bioscience AB

**The shareholders in Abera Bioscience AB, reg. no. 556909-0904 ("Company"), are hereby invited to attend the Annual General Meeting Wednesday 10<sup>th</sup> of June 2026 at 13.00 in Uppsala Business Park, Virdings allé 32 in Uppsala.**

### Registration and the right to participate

The person who has the right to participate in the Annual General Meeting

- must be entered in the share register kept by Euroclear Sweden AB on Monday 1<sup>st</sup> of June 2026, and
- has no later than Tuesday June 9, 2026, registered for the Annual General Meeting by e-mail to [maria.alriksson@aberabio.com](mailto:maria.alriksson@aberabio.com) or by post to Abera Bioscience AB (publ), "Annual General Meeting 2026", Virdings allé 32, 754 50 Uppsala, Sweden

When register, the name, personal or organization number and number of shares to be represented must be stated, as well as, where applicable, information about a deputy, representative or assistant.

### Nominee-registered shares

Shareholders with nominee-registered shares must request from the nominee to enter the share register with Euroclear Sweden AB in order to be able to participate in the Annual General Meeting (registration of voting rights). Shareholders must therefore contact the nominee in good time and register their shares with their voting rights in accordance with the nominee's instructions.

### Powers of attorney and authorization documents

Shareholders who are unable to attend the Annual General Meeting in person may appoint one or more proxies. In such cases, shareholders must issue a written, dated and signed power of attorney for each proxy. The original power of attorney must be mailed to the Company and be received by the Company no later than Wednesday June 3, 2026. Anyone representing a legal entity must also enclose a copy of the registration certificate or equivalent authorization documents showing authorized signatories.

### Proposed Agenda

1. Election of Chairman of the Meeting
2. Preparation and approval of the voting list
3. Election of one or more persons to attest the minutes
4. Consideration of whether the meeting has been duly convened
5. Approval of the Agenda
6. Presentation of the Annual report and Audit report
7. Resolution regarding
  - a. Determination of the Income statement and Balance sheet
  - b. Allocations of the Company's result according to the adopted Balance sheet
  - c. Discharge from liability for the Company's Board of Directors and CEO
8. Determination of the numbers of Board members and Auditors and any deputies.
9. Determination of remuneration for the Board and Auditors
10. Election of
  - a. Board of Directors and deputies
  - b. Auditors and deputy auditors
11. Resolution authorizing the Board of Directors
12. Closing of the General Meeting

## Proposals

### **Proposal of item 8; Determination of number of board members and auditors**

Proposed that the board consist of four members whereof one is chairman of the board. Suggested that the Company has one Auditing Company and that no deputies are elected.

### **Proposal of item 9; Determination of remuneration for the Board and auditors**

Proposed that remuneration of 200 000 sek per year to the chairman of the board and 100 000 sek per year to each board member shall be paid.

Fees to the auditor shall be paid in accordance with by the auditing Company issued and by Abera Bioscience AB approved fee note.

### **Proposal of item 10a and 10b; Election of a. Board of Directors and b. Auditor**

- a. Proposed to re-election of Anders Ericson (chairman), Cristina Glad, Harry Råstedt and Fredrik Juserius and to new election of Mats Wahlström.
- b. Proposed to elect of Öhrlings Pricewaterhousecoopers AB as audit firm for the period up until the next Annual General Meeting.

### **Proposal of item 11; Resolution authorizing the Board of Directors**

Proposed that the Board be authorized, until the next Annual General Meeting, to on one or more occasions, issue shares, warrants or convertibles, with or without preferential rights for shareholders, and within the limits of the Articles of Association, paid in cash, in kind or by set-off.

A valid decision requires that the proposal is supported by shareholders with at least two thirds of both the votes and the shares represented at the Annual General Meeting.

\*\*\*

Stockholm, May 2026  
Abera Bioscience AB  
The Board of Directors